View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Noble Life Sciences
22 December 2020

Noble Life Sciences and George Mason University Collaborate to Access the NCBID BSL-3 Facility

Noble Life Sciences (NLS) is pleased to announce that it has signed a Collaboration Agreement with George Mason University (Mason). The collaboration will allow access the National Center for Biodefense and Infectious Diseases (NCBID) BSL-3 facility located within their Biomedical Research Laboratory at Mason’s Science and Technology Campus in Manassas. The Agreement enables NLS to perform federal and non-federally funded BSL-3 animal model projects to support the development of new antiviral and antibacterial agents against infectious and resistant pathogens.

Additionally, NLS and Mason have agreed to explore collaborative research opportunities in the following areas

  • Development of animal models for viral diseases.
  • Development of animal tissue-based and cell culture-based assay methodologies for the assessment of the efficacy of vaccines and therapeutics for viral agents.
  • Assay and reagent development for quantification of viral RNA and/or protein.

“Access to the BSL-3 facility through this collaboration agreement with Mason will enable NLS to provide preclinical testing services in support of an immediate need for the development of coronavirus vaccines and therapeutics as well as other emerging infectious diseases,” said Srujana Cherukuri, Chief Executive Officer at NLS

“The collaboration with Noble Life Sciences opens doors to new opportunities for the development of novel therapeutics and diagnostics by Mason scientists and enables us to partner with an entity that has extensive experience bringing such new discoveries to the marketplace,” said Ali Andalibi, Chief Scientific Officer of the BRL and Senior Associate Dean in Mason’s College of Science.

For more information, please fill out the enquiry form attached to this page.

Diabetes is confirmed by both an absence of insulin and increase in blood glucose levels.
Skin serves as a barrier between the external environment and the underlying tissues. When the integrity of the skin is disrupted this barrier is compromised.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena